Oxaliplatin Does Not Benefit Older Patients With Metastatic Colorectal Cancer
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE improved responses and survival outcomes.
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
The improvement in response did not translate to a survival benefit.
Adjuvant S-1 improved survival over surgery alone.
Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.